Psammaplysin F can substantially affect chemotherapy-resistant cancer cells by decreasing phosphorylated eIF2α, reducing the quantity of SGs, and improving the effectiveness of bortezomib and sorafenib. The gene discussed is EIF2A; the disease is cancer.